Tumor-infiltrating CCR2+ inflammatory monocytes counteract specific immunotherapy

Frontiers in Immunology

Immunology

Ann-Kathrin Hartmann¹  Joschka Bartneck¹  Markus Philipp Radsak¹  Sabine Muth²  Hans-Christian Probst²  Lara Stein²  Danielle Arnold-Schild²  Michael Stassen²  Hansjörg Schild²  Matthias Klein²  Federico Marini³  Jonas Pielenhofer⁴  Peter Langguth⁴  Sophie Luise Meiser⁴  Matthias Mack⁵ 

[1] III Department of Medicine - Hematology, Oncology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany;Institute of Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany;Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg-University, Mainz, Germany;Institute of Pharmaceutical and Biomedical Sciences of the Johannes Gutenberg-University, Biopharmaceutics and Pharmaceutical Technology, Mainz, Germany;University Hospital Regensburg, Department Nephrology, Regensburg, Germany;

关键词: cancer immunotherapy;    transcutaneous immunization;    tumor micro environment (TME);    immune evasion;    CCR2 monocytes +;   

DOI  :  10.3389/fimmu.2023.1267866

 received in 2023-07-27, accepted in 2023-09-13,  发布年份 2023

来源: Frontiers

【 摘 要 】

Tumor development and progression is shaped by the tumor microenvironment (TME), a heterogeneous assembly of infiltrating and resident host cells, their secreted mediators and intercellular matrix. In this context, tumors are infiltrated by various immune cells with either pro-tumoral or anti-tumoral functions. Recently, we published our non-invasive immunization platform DIVA suitable as a therapeutic vaccination method, further optimized by repeated application (DIVA2). In our present work, we revealed the therapeutic effect of DIVA2 in an MC38 tumor model and specifically focused on the mechanisms induced in the TME after immunization. DIVA2 resulted in transient tumor control followed by an immune evasion phase within three weeks after the initial tumor inoculation. High-dimensional flow cytometry analysis and single-cell mRNA-sequencing of tumor-infiltrating leukocytes revealed cytotoxic CD8+ T cells as key players in the immune control phase. In the immune evasion phase, inflammatory CCR2+ PDL-1+ monocytes with immunosuppressive properties were recruited into the tumor leading to suppression of DIVA2-induced tumor-reactive T cells. Depletion of CCR2+ cells with specific antibodies resulted in prolonged survival revealing CCR2+ monocytes as important for tumor immune escape in the TME. In summary, the present work provides a platform for generating a strong antigen-specific primary and memory T cell immune response using the optimized transcutaneous immunization method DIVA2. This enables protection against tumors by therapeutic immune control of solid tumors and highlights the immunosuppressive influence of tumor infiltrating CCR2+ monocytes that need to be inactivated in addition for successful cancer immunotherapy.

【 授权许可】

Unknown   
Copyright © 2023 Bartneck, Hartmann, Stein, Arnold-Schild, Klein, Stassen, Marini, Pielenhofer, Meiser, Langguth, Mack, Muth, Probst, Schild and Radsak